Takeda unveils secondary endpoint data from Phase III PsO pill trials

Phase 3positivePsO pillPositive

AI Analysis

Summary

Takeda announced positive secondary endpoint data from Phase III trials of its psoriasis oral pill, demonstrating efficacy in high-impact skin areas including scalp, palms, and soles.

Clinical Trial Data

Phase

Phase 3

Outcome Details

Key secondary endpoints met in high-impact areas including scalp, palms, and soles

Importance:6/10

Sentiment:

0.60

psoriasisoral therapysecondary endpointsphase 3 data

Related Companies

$TAK

Read the original article

Published by Clinical Trials Arena on July 17, 2026 9:57 AM

Read Original